Page 3 - Scientific Library
Which Histone (De)Methyltransferase modulators to choose?
Histone Methyltransferases (ex. EZH1 and EZH2, and G9a) and their counter-parts (Histone demethylases like JARID1, the KDM4, and the JMJD family) have become promising targets for inhibitor screenings,
Histone Deacetylases (HDACs) and Alzheimer
In a recent post, I concentrated on the role of HDACs in cancer: Histone Deacetylases (HDACs) and Cancer and mentioned that some HDACs are overexpressed and show very high activities in a number of tumours.
6 active compounds to rediscover rare bacterial metabolites
Microbial metabolites are a source of unequalled elements for in vitro assays. Sometimes  neglected, these active molecules naturally provide a large spectrum of structural diversity for Drug discovery
Is tumour immune evasion mediated by p53/miR-34/PDL1 interaction?
Tumour immune evasion can be mediated by a complex set of interaction involving p53, miR-34 and PDL1. This is the conclusion of a work by Cortez et al. and recently published in JCNI .
The involvement
Cancer Immunotherapy: Generate your PD-L1 target cell line
In a recent post,  I invited you to discover a cell line provided by BPS Bioscience over-expressing the checkpoint
Microbial K-Ras Inhibitors
Small molecules known to modulate biological activies of the K-Ras oncogene are predominantly of synthetic origin (ex. Salirasib). Nevetheless, various publications have recently demontrated the biological
New research tools targeting PCSK9 and LDLR
There is an increasing demand for new cholesterol-lowering therapies in addition to existing treatments (e.g. targeting statins). The pharmacological inhibition of PCSK9-mediated LDLR degradation